Nov 9, 2026 4:01 pm EST Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
Nov 4, 2026 7:00 am EST Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
Oct 29, 2026 4:01 pm EDT Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Sep 14, 2026 7:00 am EDT Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder